AI could make ovarian cancer surgery safer by guiding fluids and blood pressure

NCT ID NCT07070973

Recruiting now Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether an AI-based system can help doctors better manage fluids and blood pressure during complex ovarian cancer surgery. The system uses special software to guide fluid infusions and predict drops in blood pressure. The goal is to reduce complications like kidney injury and fluid overload. The study will compare results from 52 patients to a historical group of 50 patients who received standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Assisted Fluid Management software and Hypotension Prediction Index
What this could lead to: If successful, this could lead to a safer way to manage fluids and blood pressure during complex ovarian cancer surgery, potentially reducing complications like kidney injury and fluid overload.
What could go wrong: This is a small pilot study (52 participants) comparing results to past patients, not a large randomized trial. The AI tools may not improve outcomes as expected, and results may not apply to all hospitals or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FLUID OVERLOAD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Edema ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FLUID OVERLOAD HEMODYNAMIC INSTABILITY OVARIAN CANCER

Contacts and locations

Locations

IRCCS Fondazione Policlinico A. Gemelli
RECRUITING

Rome, 00167, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.